GlassScriptPhysician profile
Katye L Herring
NPI 1164884557
$1,154.48
in general payments reported to CMS, 2019-2025
17 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.18 · 2022: $25.88 · 2023: $204 · 2024: $585 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $313.97 | 2023-2025 | |
| Novo Nordisk INC | $171.97 | 2022-2025 | |
| Pharming Healthcare, INC. | $115.06 | 2024 | Joenja |
| Jazz Pharmaceuticals INC. | $83.81 | 2024 | |
| Csl Behring | $79.80 | 2023-2024 | Hemgenix, Idelvion, Afstyla |
| Pfizer INC. | $75.09 | 2019-2024 | |
| Day One Biopharmaceuticals | $69.90 | 2024-2025 | Ojemda |
| Octapharma USA, INC. | $34.34 | 2024 | Balfaxar, Octagam Immune Globulin (Human) |
| Uswm, LLC | $33.19 | 2025 | Iwilfin |
| Alexion Pharmaceuticals, INC. | $32.66 | 2022-2023 | Ultomiris |
| Biomarin Pharmaceutical INC. | $28.41 | 2023 | Roctavian |
| Syndax Pharmaceuticals, INC. | $22.80 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.90 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.14 | 2024 | Vpriv |
| Springworks Therapeutics, INC. | $18.76 | 2025 | Gomekli |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $18.20 | 2023 | |
| Azurity Pharmaceuticals, INC. | $15.48 | 2024 | Xatmep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katye Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.